The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28231524 |
6 |
Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening. |
West China Hospital of Sichuan University |
27171036 |
164 |
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
University of Nebraska Medical Center |
27490956 |
59 |
Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening. |
Merck |
27326329 |
102 |
2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19. |
The Institute of Cancer Research |
26985305 |
34 |
Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells. |
Genentech |
26796641 |
55 |
Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. |
The Institute of Cancer Research |
26852363 |
72 |
Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore. |
Merck |
30639897 |
48 |
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. |
The First Affiliated Hospital of Zhengzhou University |
32502343 |
79 |
Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13. |
Harvard Medical School |
27326333 |
54 |
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8. |
Genentech |
30594029 |
42 |
CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
Shaoxing University |
32071678 |
6 |
Discovery of 4-Piperazine Isoquinoline Derivatives as Potent and Brain-Permeable Tau Prion Inhibitors with CDK8 Activity. |
University of California |
30630717 |
2 |
Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes. |
Wannan Medical College |
31895562 |
76 |
Discovery of a Novel, Highly Potent, and Selective Thieno[3,2- |
Takeda Pharmaceutical |
31622099 |
44 |
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88 |
Astrazeneca |
31526603 |
379 |
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application. |
Takeda Pharmaceutical |
29398441 |
111 |
Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4. |
Astrazeneca |
30253346 |
46 |
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. |
Chinese Academy of Sciences |
29266937 |
36 |
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
University of South Australia |
30067358 |
79 |
Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors. |
Takeda Pharmaceutical |
28302507 |
124 |
Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives. |
Takeda Pharmaceutical |
28392276 |
73 |
Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential. |
Takeda Pharmaceutical |